Skip to main content
. Author manuscript; available in PMC: 2016 Jul 15.
Published in final edited form as: Cancer Res. 2015 May 12;75(14):2897–2906. doi: 10.1158/0008-5472.CAN-14-2860

Figure 1.

Figure 1

Decitabine decreases cell viability in a time-dependent manner in a subset of cancer cell lines. A, cell viability was measured after treatment with decitabine (left) or vorinostat (right) in OVCAR8 cells. Data are representative of two independent experiments (14 replicates, mean ± SD). B, cell viability was measured for a panel of 45 solid tumor lines after treatment with decitabine. Data are representative of two independent experiments each measured in 14 replicates (mean).